DGX · Quest Diagnostics Inc

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during the Leerink 2026 Global Healthcare Conference in Miami on Wednesday, March 11, 2026, at 8:00 a.m. Eastern Time. The Fireside Chat and Q&A session will be webcast live during the conference on the company's investor relations page, which can be accessed at ir.QuestDiagnostics.com . In addition, the archived webcast will be available within 24 hours after the conclusion of the live event and will remain available until March 25, 2026. About Quest Diagnostics Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler

Fourth quarter revenues of $2.81 billion, up 7.1% from 2024 Fourth quarter reported diluted earnings per share ("EPS") of $2.18, up 11.8% from 2024; and adjusted diluted EPS of $2.42, up 8.5% from 2024 Full year revenues of $11.04 billion, up 11.8% from 2024 Full year reported diluted EPS of $8.75, up 13.8% from 2024; and adjusted diluted EPS of $9.85, up 10.3% from 2024 Full year cash from operations of $1.89 billion Full year 2026 revenues expected to be between $11.70 billion and $11.82 billion Full year 2026 reported diluted EPS expected to be between $9.45 and $9.65; and adjusted diluted EPS expected to be between $10.50 and $10.70 Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2025. "We closed 2025 with a strong fourth quarter, and delivered double-digit growth in revenues and earnings per share for the full year," said Jim Davis,

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80 per share. The increase is effective with the dividend payable on April 20, 2026 to shareholders of record of Quest Diagnostics common stock on April 6, 2026. With the increase, the annual cash dividend will be $3.44 per share. Additionally, the Board of Directors has increased the Company's share repurchase authorization by $1 billion. The increased authority is in addition to the approximately $0.4 billion that was available as of December 31, 2025 under the Company's share repurchase program. About Quest Diagnostics Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on

(NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced flow cytometry methods to assess measurable residual disease (MRD) in patients with the blood cancer myeloma (also called multiple myeloma). Called Quest Flow Cytometry MRD for Myeloma, the new test provides comparable sensitivity as next-generation sequencing methods in detecting residual myeloma*, but at a fraction of the cost, supporting better care and outcomes. "Our Flow Cytometry MRD for Myeloma test harnesses cutting-edge science and technology to deliver ultrasensitive insights from a noninvasive blood test, thereby improving care and value for patients and the healthcare system," said board-certified oncologist and hematologist Yuri Fesko, M.D., Senior Vice President and Chief Medical Officer, Quest Diagnostics. "This new test merges this elite performance with improved access, given Quest's approximately 7,000 phlebotomy sites across the

(NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been named to the Fortune ® magazine 2026 World's Most Admired Companies™ list, for the 12 th consecutive year. "Quest's recognition as one of the world's most admired companies reflects the commitment of our 55,000 colleagues to living our purpose every day: working together to create a healthier world, one life at a time," said Jim Davis, Chairman, CEO and President. "We are proud to again be named among this elite list of globally respected companies and even more proud to continue our important work at the center of healthcare, delivering diagnostic insights that illuminate a path to better health." In addition to the overall ranking, Quest ranked number two in the "Health Care: Pharmacy and Other Services" industry category. Fortune's World's Most Admired recognition is based on nine key attributes related to corporate reputation, including quality of products and services, innovation,

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.QuestDiagnostics.com/investor . The company suggests participants dial in approximately 10 minutes before the call. A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 866-388-5361 for domestic callers or 203-369-0416 for international callers; no passcode is required. Telephone replays will be available from approximately 10:30 a.m. Eastern Time on February 10, 2026 until midnight Eastern

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that data will be shared on circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing during two poster presentations at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA., and online. The studies evaluate the use of ctDNA in colorectal cancer using the Haystack MRD® test from Quest Diagnostics. Details of the poster presentations are as follows: Title: Reproducibility and Clinical Concordance of a Tumor-Informed MRD Assay in Patients with Resected Colorectal Cancer from the DYNAMIC Trials Abstract Number: 26 Lead Author: Jeanne Tie, MBChB, FRACP, MD Session Time and Date: 1/10/2026, 12:00 PM-1:30 PM (PST) Title: Use of circulating tumor DNA (ctDNA) to monitor patients undergoing total neoadjuvant treatment (TNT) for locally advanced rectal adenocarcinoma (LARC). Abstract Number: 30 Lead

Corewell Health and Quest Diagnostics (NYSE: DGX) today announced the completion of the previously announced transaction to establish a laboratory services joint venture to expand access to innovative, quality and affordable laboratory services in Michigan. Equity ownership of the joint venture, named Diagnostic Lab of Michigan, LLC, will be shared 51% by Quest and 49% by Corewell Health. Quest and Corewell Health's existing laboratories will continue to provide lab services to the joint venture until a future 100,000-square-foot state-of-the-art laboratory facility at the Corewell Health Southfield Center in Southfield, Michigan opens in the first quarter of 2027. In addition, Quest's Collaborative Lab Solutions (Co-Lab) hospital lab management services have begun to take effect across all 21 Corewell Health hospitals. Quest has also begun to deploy initiatives incorporating a comprehensive suite of Co-Lab Solutions for Corewell Health, including supply chain, lab management, patient